Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines

Stephen J Schuster, MD, Nancy L Bartlett, MD, Sarit Assouline, MD, Sung-Soo Yoon, MD PhD, Francesc Bosch, MD PhD, Laurie H Sehn, MD, Chan Y. Cheah, Mazyar Shadman, MD MPH, Gareth P Gregory, MBBS (Hons), PhD FRACP, FRCPA, Matthew Ku, MBBS, FRACP, FRCPA, PhD, Michael C Wei, MD PhD, Shen Yin, PhD, Antonia Kwan, MD PhD MRCPCH, Kasra Yousefi, MSc, Genevive Hernandez, PhD, Chi-Chung Li, PhD, Carol O'Hear, MD PhD, Lihua E Budde, MD PhD

Blood (2019) 134 (Supplement_1): 6.

https://doi.org/10.1182/blood-2019-123742

Published: 2019

Journal Articles

Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma

Chi-Chung Li, PhD, Brendan Bender, PhD, Shen Yin, PhD, Zao Li, PhD, Cindy Zhang, MS, Genevive Hernandez, PhD, Antonia Kwan, MD PhD MRCPCH, Laura Sun, PhD, Joanne I Adamkewicz, PhD, Hong Wang, MD PhD DABT, Natalie Dimier, PhD, Sue-Zen Lim, BPharm, Carol O'Hear, MD PhD, Laurie H Sehn, MD, Ian W. Flinn, MD PhD, Sung-Soo Yoon, MD PhD, Lihua E Budde, MD PhD, Chunze Li, PhD, Michael C Wei, MD PhD

Blood (2019) 134 (Supplement_1): 1285.

https://doi.org/10.1182/blood-2019-123961

Published: 2019

Journal Articles

Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma

Blood (2019) 134 (Supplement_1): 1585.

https://doi.org/10.1182/blood-2019-123933

Published: 2019

Journal Articles

An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3 Bispecific Antibody) Development Program in Relation to Neurotoxicity Risk

Catherine Diefenbach, MD, Sarit Assouline, MD, Francesc Bosch, MD PhD, Chan Y. Cheah, Won Seog Kim, MD PhD, Matthew J Matasar, MD, Carlos Panizo, MD PhD, Dok Hyun Yoon, MD PhD, Brendan Bender, PhD, Genevive Hernandez, PhD, Chi-Chung Li, PhD, Bruce McCall, MD, Carol O'Hear, MD PhD, Michael C Wei, MD PhD, Shen Yin, PhD, Kasra Yousefi, MSc, Antonia Kwan, MD PhD MRCPCH, Loretta J. Nastoupil, MD MSc

Blood (2019) 134 (Supplement_1): 4728.

https://doi.org/10.1182/blood-2019-123757

Published: 2019

Journal Articles

Oncogenic Role for the Lck/ZAP70/PLCG2 Signaling Pathway in Pre-B-ALL Pathogenesis

Jesus Duque-Afonso, MD, Michael C. Wei, MD PhD, Chiou-Hong Lin, PhD, Jue Feng, PhD, Corina Buechele, MD, Stephen Hon-Kit Wong, PhD, Michael C Bassik, PhD, Michael L. Cleary, MD

Blood (2015) 126 (23): 810.

https://doi.org/10.1182/blood.V126.23.810.810

Published: 2015

Journal Articles

Next-Generation NAMPT Inhibitors For ALL Identified By Sequential High-Throughput Phenotypic Chemical and Functional Genomic Screens

Michael C. Wei, MD, PhD, Christina J. Matheny, PhD, Michael C. Bassik, PhD, Alicia J. Donnelly, PhD, Martin Kampmann, PhD, Masayuki Iwasaki, PhD, MSC, Obdulio Piloto, PhD, David E. Solow-Cordero, PhD, Donna Bouley, DVM, PhD, Rachel E. Rau, MD, Patrick Brown, MD, Michael T. McManus, PhD, Jonathan S. Weissman, PhD, Michael L. Cleary, MD

Blood (2013) 122 (21): 171.

https://doi.org/10.1182/blood.V122.21.171.171

Published: 2013

Journal Articles

High Throughput Sequencing of Acute Lymphoblastic Leukemia Small RNAs.

Michael C Wei, MD, PhD, Elizabeth O Osborn, Michael Cleary, MD

Blood (2010) 116 (21): 3650.

https://doi.org/10.1182/blood.V116.21.3650.3650

Published: 2010

NARROW

Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines

Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma

Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma

An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3 Bispecific Antibody) Development Program in Relation to Neurotoxicity Risk

Oncogenic Role for the Lck/ZAP70/PLCG2 Signaling Pathway in Pre-B-ALL Pathogenesis

Next-Generation NAMPT Inhibitors For ALL Identified By Sequential High-Throughput Phenotypic Chemical and Functional Genomic Screens

High Throughput Sequencing of Acute Lymphoblastic Leukemia Small RNAs.

Email alerts

ASH Publications

American Society of Hematology

Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines

Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma

Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma

An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3 Bispecific Antibody) Development Program in Relation to Neurotoxicity Risk

Oncogenic Role for the Lck/ZAP70/PLCG2 Signaling Pathway in Pre-B-ALL Pathogenesis

Next-Generation NAMPT Inhibitors For ALL Identified By Sequential High-Throughput Phenotypic Chemical and Functional Genomic Screens

High Throughput Sequencing of Acute Lymphoblastic Leukemia Small RNAs.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only